Behn & Wyetzner, Chartered

Representing Qui Tam whistleblowers

  • Chicago’s Behn & Wyetzner
  • Whistleblower Attorneys | Chicago, IL | Behn Wyetzner, Chartered
  • Qui Tam Whistleblower Compensation Awards | Behn Wyetzner, Chartered
  • Our Clients
  • FAQs for Whistleblowers
  • History of the Federal False Claims Act
  • Retaining Chicago’s Behn & Wyetzner
Home / Qui Tam Whistleblower Compensation Awards | Behn Wyetzner, Chartered / The Omnicare Kickbacks Case

The Omnicare Kickbacks Case

qui tam action involving kickbacks

Recovery Amount: $98 Million

Qui Tam Action Involving Kickbacks for Antipsychotic Drugs

Omnicare, Inc. calls itself, “the nation’s leading provider of pharmaceutical care for the elderly.” In the past three years it has settled two major Medicaid fraud cases brought by pharmacist-whistleblower Bernard Lisitza, who after reporting improper practices had been fired by Omnicare. Qui tam attorneys, Michael I. Behn and Linda Wyetzner of Behn & Wyetzner, Chartered, in Chicago, represent Mr. Lisitza.

In November 2009 Omnicare paid $98 million to settle charges that the pharmacy committed Medicaid fraud through several kickback schemes, including Lisitza‘s allegation that pharmaceutical manufacturer Johnson & Johnson (“J&J”) paid Omnicare to increase sales of J&J’s Risperdal® anti-psychotic. (District of Massachusetts, No. 07-10026-RGS). The payments allegedly induced Omnicare pharmacies to switch patients from other anti-psychotic medications to Risperdal®.

The 2009 settlement resolved Lisitza‘s allegations that J&J made quarterly rebate payments on Omnicare’s purchases of Risperdal® under rebate agreements both entities executed in April 1997 and March 2000. The agreements conditioned rebate payment upon Omnicare’s engaging in an “active intervention program” to convince physicians to prescribe Risperdal® and requiring that all competitive anti-psychotic products be “Prior Authorized for Risperdal® failure,” according to the complaint. The government alleged that Omnicare failed to disclose to physicians that such intervention activities were a condition of it receiving such rebate payments.

In November 2006 Omnicare paid $49.5 million to settle Medicaid fraud charges that it illegally switched the drugs of senior citizens in nursing homes and other facilities. The charges primarily involved generic forms of the popular drugs Zantac® and Prozac®. Lisitza was the pharmacist-whistleblower in that case, too.

Supplementary Files:

  • Omnicare Kickbacks Company Press Release
  • Omnicare Kickbacks Complaint
  • Omnicare Kickbacks Federal News Release
  • Omnicare Kickbacks Federal Settlement
  • Omnicare Kickbacks News Release
  • Edelweiss Illinois
  • The CVS Case
  • The Johnson & Johnson Case
  • The Leo Burnett Case
  • The Northrop-Grumman Case
  • The Northwestern University Case
  • The Omnicare Kickbacks Case
  • The Omnicare Switching Case
  • The Walgreens Case
  • The Walgreens Case II
  • The Quest Diagnostics Case
  • Leading Lawyers
Do You Have a Case? How Can We Help? Act Now
10 North Dearborn Street, 6th Floor, Chicago, IL 60602
Phone: 312.629.0000
FAX: 312.629.0000
info@behnwyetzner.com
  • Firm Experience
  • Attorneys
  • Qui Tam Whistleblower Compensation Awards | Behn Wyetzner, Chartered
  • Our Clients
  • Whisleblower FAQs
  • False Claims Act
  • Blog
  • Accessibility
  • Contact Us
Website Design by ePageCity